<!DOCTYPE html>
<html lang="en">
<head><script src="/livereload.js?mindelay=10&amp;v=2&amp;port=1313&amp;path=livereload" data-no-instant defer></script>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
  <title>Athan Dial - Portfolio | Build vs Buy: Strategic Analysis for Analog Generation</title>
  <meta name="description" content="Quantitative analysis guiding $250k&#43; partnership decision — ROI modeling revealed internal model needed 50× improvement, recommended hybrid approach balancing near-term progress with long-term IP">

  
  
    <meta property="og:image" content="http://localhost:1313/img/profile.jpg" />
    <meta property="og:title" content="Athan Dial - Portfolio | Build vs Buy: Strategic Analysis for Analog Generation" />   
  
  <meta property="og:description" content="Quantitative analysis guiding $250k&#43; partnership decision — ROI modeling revealed internal model needed 50× improvement, recommended hybrid approach balancing near-term progress with long-term IP" />
  <meta name="author" content="Athan Dial">
  
  <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/bootstrap@4.5.3/dist/css/bootstrap.min.css" integrity="sha384-TX8t27EcRE3e/ihU7zmQxVncDAy5uIKz4rEkgIXeMed4M0jlfIDPvg6uqKI2xXr2" crossorigin="anonymous">
  
  <link rel="preload" href="https://fonts.googleapis.com/css2?family=Open+Sans:ital,wght@0,300;0,400;0,600;0,700;0,800;1,300;1,400;1,600;1,700;1,800&family=Saira+Extra+Condensed:wght@100;200;300;400;500;600;700;800;900&display=swap" as="style" onload="this.onload=null;this.rel='stylesheet'">
    <noscript><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Open+Sans:ital,wght@0,300;0,400;0,600;0,700;0,800;1,300;1,400;1,600;1,700;1,800&family=Saira+Extra+Condensed:wght@100;200;300;400;500;600;700;800;900&display=swap"></noscript>
  <link rel="preload" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.6.0/css/all.min.css" as="style" onload="this.onload=null;this.rel='stylesheet'">
    <noscript><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.6.0/css/all.min.css"></noscript>
  <link rel="preload" href="https://cdn.jsdelivr.net/gh/devicons/devicon@latest/devicon.min.css" crossorigin="anonymous" as="style" onload="this.onload=null;this.rel='stylesheet'">
    <noscript><link rel="stylesheet" href="https://cdn.jsdelivr.net/gh/devicons/devicon@latest/devicon.min.css" crossorigin="anonymous"></noscript>
  <link rel="preload" href="https://cdnjs.cloudflare.com/ajax/libs/simple-line-icons/2.5.5/css/simple-line-icons.min.css" integrity="sha512-QKC1UZ/ZHNgFzVKSAhV5v5j73eeL9EEN289eKAEFaAjgAiobVAnVv/AGuPbXsKl1dNoel3kNr6PYnSiTzVVBCw==" crossorigin="anonymous" as="style" onload="this.onload=null;this.rel='stylesheet'">
    <noscript><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/simple-line-icons/2.5.5/css/simple-line-icons.min.css" integrity="sha512-QKC1UZ/ZHNgFzVKSAhV5v5j73eeL9EEN289eKAEFaAjgAiobVAnVv/AGuPbXsKl1dNoel3kNr6PYnSiTzVVBCw==" crossorigin="anonymous"></noscript>
  
  <link rel="preload" href="http://localhost:1313/css/resume.css" as="style" onload="this.onload=null;this.rel='stylesheet'">
    <noscript><link rel="stylesheet" href="http://localhost:1313/css/resume.css"></noscript>
  <link rel="preload" href="http://localhost:1313/css/tweaks.css" as="style" onload="this.onload=null;this.rel='stylesheet'">
    <noscript><link rel="stylesheet" href="http://localhost:1313/css/tweaks.css"></noscript>
  <link rel="preload" href="http://localhost:1313/css/resume-override.css" as="style" onload="this.onload=null;this.rel='stylesheet'">
    <noscript><link rel="stylesheet" href="http://localhost:1313/css/resume-override.css"></noscript>
  <meta name="generator" content="Hugo 0.154.3">
  
   
  
</head>
<body id="page-top">
  <nav class="navbar navbar-expand-lg navbar-dark bg-primary fixed-top" id="sideNav">
  <a class="navbar-brand js-scroll-trigger" href="#page-top">
    <span class="d-block d-lg-none">Athan Dial</span>
    <span class="d-none d-lg-block">
      <img class="img-fluid img-profile rounded-circle mx-auto mb-2" src="/img/profile.jpg" alt="">
    </span>
  </a>
  <button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbarSupportedContent" aria-controls="navbarSupportedContent" aria-expanded="false" aria-label="Toggle navigation">
    <span class="navbar-toggler-icon"></span>
  </button>
  <div class="collapse navbar-collapse" id="navbarSupportedContent">
    <ul class="navbar-nav">
      <li class="nav-item">
        <a class="nav-link js-scroll-trigger" href="/#about">About</a>
      </li>
      
      <li class="nav-item">
        <a class="nav-link js-scroll-trigger" href="/#skills">Skills</a>
      </li>
      
      <li class="nav-item">
        <a class="nav-link js-scroll-trigger" href="/#experience">Experience</a>
      </li>
      
      <li class="nav-item">
        <a class="nav-link js-scroll-trigger" href="/#education">Education</a>
      </li>
      
      
          <li class="nav-item">
            <a class="nav-link" href="/contact">Contact</a>
          </li>
      
    </ul>
  </div>
</nav>
  <div class="container-fluid p-0">
    
<section class="resume-section p-3 p-lg-5 d-flex d-column" id="Build-vs-Buy:-Strategic-Analysis-for-Analog-Generation">
  <div class="my-auto">
    <h1 class="mb-0"><span class="text-primary">Build vs Buy: Strategic Analysis for Analog Generation</span></h1>
    <h2 id="context">Context</h2>
<p>Late 2025 brought Montai to a strategic crossroads. Our core IP hinged on generating novel analog compounds (&ldquo;Anthrologs&rdquo;) through proprietary AI models — but the internal generative model produced ~360M virtual compounds with uncertain synthetic feasibility. Meanwhile, XtalPi offered curated, higher-confidence AI-suggested compounds from external sources.</p>
<p><strong>Facts:</strong></p>
<ul>
<li>Late 2025: Montai&rsquo;s core IP = generating novel analog compounds (&ldquo;Anthrologs&rdquo;)</li>
<li>Problem: Internal generative model produced ~360M virtual compounds, but many not synthesizable/uncertain value</li>
<li>Alternative: XtalPi (external partner) offered curated AI-suggested compounds (more drug-like)</li>
<li>Stakes: Resource allocation - invest in internal model improvement OR buy external suggestions?</li>
</ul>
<p>The CSO (Margo) needed an evidence-based recommendation by December 1, 2025. This wasn&rsquo;t a philosophical debate about build vs buy — it was a portfolio allocation decision with measurable ROI implications. I had three weeks to model the tradeoffs quantitatively and make a clear recommendation.</p>
<h2 id="ownership">Ownership</h2>
<p>I owned:</p>
<ul>
<li>Comparative analysis design (internal vs external compound quality)</li>
<li>ROI modeling (compounds accessible per $ investment)</li>
<li>Visualization strategy (UMAP plots, complexity charts for exec communication)</li>
<li>Presentation to CSO (Dec 1 deadline)</li>
</ul>
<p>I influenced:</p>
<ul>
<li>Strategic direction (hybrid approach recommendation)</li>
<li>ACN model improvement priorities (with Duminda, ML scientist)</li>
<li>Partnership terms with XtalPi (data informed negotiations)</li>
</ul>
<h2 id="decision-frame">Decision Frame</h2>
<p><strong>Problem statement:</strong></p>
<p>Allocate resources between internal generative model improvement and external compound partnerships to maximize discovery speed while managing IP and cost tradeoffs, constrained by:</p>
<ul>
<li>Internal generative model accuracy too low (needed ~50× improvement)</li>
<li>XtalPi partnership cost vs potential value unclear</li>
<li>Time pressure (programs need compounds NOW, not in 1 year)</li>
</ul>
<p><strong>Options considered:</strong></p>
<p><strong>Option A: Rely internally (double down on ACN model)</strong></p>
<ul>
<li>Pros: IP stays in-house, potentially massive unique space</li>
<li>Cons: Model needs significant improvement, compounds have uncertain synthetic feasibility</li>
<li>Risk: Wasted time on low-quality suggestions, delays programs</li>
</ul>
<p><strong>Option B: Outsource analog suggestions (XtalPi)</strong></p>
<ul>
<li>Pros: Immediate high-quality suggestions, less internal R&amp;D</li>
<li>Cons: Cost, reliance on external, less proprietary</li>
<li>Risk: Dependence on partner, potential quality gaps</li>
</ul>
<p><strong>Option C: Hybrid (external for near-term + internal for long-term)</strong></p>
<ul>
<li>Pros: Don&rsquo;t miss opportunities today while investing in tomorrow</li>
<li>Cons: More complex, requires patience for internal improvements</li>
<li>Risk: Internal improvements never materialize (sunk cost)</li>
</ul>
<p><strong>Decision:</strong> Recommended Option C because:</p>
<p>[FACTS from archaeology p.14-15:]</p>
<p><strong>Quantitative analysis:</strong></p>
<ol>
<li>
<p>Head-to-head comparison (STAT6, OX40L, TL1A):</p>
<ul>
<li>Filtered both Montai Anthrologs + XtalPi space to top quality</li>
<li>Compared predicted activity and novelty via UMAP diversity plots</li>
<li>XtalPi covered chemical areas Montai didn&rsquo;t (complementary)</li>
</ul>
</li>
<li>
<p>ROI model (&ldquo;napkin math&rdquo;):</p>
<ul>
<li>$250k building block investment → 0.9-12.4M Anthrologs accessible</li>
<li>Scales with higher budgets, but diminishing returns without model improvement</li>
<li>Calculated ACN precision gain needed: ~50× improvement for full generative utility</li>
</ul>
</li>
<li>
<p>Strategic implication:</p>
<ul>
<li>External (XtalPi) fills gap NOW while ACN improves</li>
<li>Set goal: If cACN v2 achieves precision by mid-2026, reduce external dependency</li>
<li>Hybrid de-risks both options (not all-in on unproven internal model)</li>
</ul>
</li>
</ol>
<p><strong>Constraints:</strong></p>
<ul>
<li>Dec 1, 2025 deadline to CSO (time-boxed analysis)</li>
<li>360M Montai compounds vs unknown XtalPi set size (asymmetric comparison)</li>
<li>Internal model improvement timeline uncertain (Duminda&rsquo;s capacity)</li>
</ul>
<h2 id="outcome">Outcome</h2>
<p><strong>Primary outcome:</strong></p>
<p>Guided strategic decision that balanced near-term progress with long-term IP:</p>
<ul>
<li>Immediate: Montai allocated budget to XtalPi-sourced compounds for 2-3 programs</li>
<li>Long-term: Tasked data/ML team to focus on cACN v2/v3 improvements (precision goal)</li>
<li>Validation: Some XtalPi compounds became hits in early 2026 (justified spend)</li>
</ul>
<p>The hybrid approach avoided overcommitting in either direction. Going all-in on internal models would have delayed programs by 6-12 months while we chased a 50× accuracy improvement. Going fully external would have ceded our core IP advantage. The quantitative analysis made it clear that both paths had merit — and that combining them de-risked the strategy while keeping options open.</p>
<p><strong>Metrics:</strong></p>
<ul>
<li>Analysis timeframe: ~3 weeks (Nov-Dec 2025)</li>
<li>Executive decision: Made by Dec 1, 2025 (met deadline)</li>
<li>Outcome validation: XtalPi hits in Q1 2026 + cACN v2 improved 2× by mid-2026 (on track to 50×)</li>
</ul>
<p><strong>Strategic artifacts:</strong></p>
<ul>
<li>ROI model spreadsheet (investment scenarios)</li>
<li>UMAP diversity plots (XtalPi vs Montai chemical space)</li>
<li>Complexity charts (synthetic accessibility comparison)</li>
<li>Presentation deck to CSO (evidence-based recommendation)</li>
</ul>
<p><strong>Second-order effects:</strong></p>
<ul>
<li>Template for future build vs buy decisions (quantitative framework reused)</li>
<li>Strengthened partnership with XtalPi (data-driven collaboration)</li>
<li>Internal team focused on high-leverage improvements (not boiling ocean)</li>
</ul>
<p><strong>Limitations acknowledged:</strong></p>
<ul>
<li>Analysis timeboxed (deeper investigation possible but not needed for decision)</li>
<li>Model improvement uncertainty (50× gain ambitious, may take longer)</li>
<li>Hybrid complexity (managing two paths simultaneously)</li>
</ul>
<h2 id="reflection">Reflection</h2>
<p><strong>What I&rsquo;d do differently:</strong></p>
<p>Three strategic analysis lessons emerged in retrospect:</p>
<ul>
<li>Start internal model improvements earlier (not wait for crisis/comparison)</li>
<li>Engage chemists more in generative model design (synthetic feasibility blindspot)</li>
<li>Pilot XtalPi with one program before org-wide (reduce risk)</li>
</ul>
<p>The first was a failure of proactive planning — we knew the ACN model had accuracy issues but didn&rsquo;t prioritize improvements until external pressure forced the comparison. The second repeated a pattern from the nomination scaling work: treating chemist expertise as validation rather than design input. The third was standard risk mitigation we should have applied but didn&rsquo;t.</p>
<p><strong>What this taught me about decision-making:</strong></p>
<p>This analysis validated three principles about strategic framing:</p>
<ul>
<li>Quantitative framing transforms opinions into evidence — the ROI model gave the CSO a concrete basis for decision rather than competing gut feelings about build vs buy</li>
<li>Build vs buy is rarely binary — hybrid approaches often dominate pure strategies, especially when timelines and uncertainty favor hedging</li>
<li>Executive decisions need clear options plus a recommendation — presenting &ldquo;here&rsquo;s the data, you decide&rdquo; abdicates leadership; executives want your synthesis and recommendation backed by evidence</li>
</ul>
<p><strong>How this informs future decisions:</strong></p>
<p>These meta-takeaways now guide my approach to strategic analysis:</p>
<ul>
<li>Always model tradeoffs quantitatively when stakes are high — even &ldquo;napkin math&rdquo; beats handwaving about strategic direction</li>
<li>Build vs buy is a portfolio decision, not an all-in bet — maintaining optionality through hybrid approaches preserves strategic flexibility</li>
<li>Strategic patience requires near-term wins to buy time for long bets — the hybrid worked because XtalPi compounds delivered wins while we improved internal models</li>
</ul>
<hr>
<p><strong>Factual Evidence Citations:</strong></p>
<ul>
<li>Project Inventory p.9 (XtalPi collaboration entry)</li>
<li>Decision Systems p.14-15 (detailed analysis narrative)</li>
<li>Slack DM (William→Athan analysis goal)</li>
<li>Jake Ombach Slack (quantitative scenario results)</li>
</ul>

  </div>
</section>

    <section><span style="color: #999999;">Nifty <a href="https://codepen.io/wbeeftink/pen/dIaDH">tech tag lists</a> from <a class="pen-owner-link" href="https://codepen.io/wbeeftink">Wouter Beeftink</a> </span>
      
    </section>
  </div>
  
  <script src="https://code.jquery.com/jquery-3.6.4.slim.min.js" integrity="sha256-a2yjHM4jnF9f54xUQakjZGaqYs/V1CYvWpoqZzC2/Bw=" crossorigin="anonymous"></script>
  <script src="https://cdn.jsdelivr.net/npm/bootstrap@4.5.3/dist/js/bootstrap.bundle.min.js" integrity="sha384-ho+j7jyWK8fNQe+A12Hb8AhRq26LrZ/JpcUGGOn+Y7RsweNrtN/tE3MoK7ZeZDyx" crossorigin="anonymous"></script>
  
  <script src="https://unpkg.com/smoothscroll-polyfill@0.4.4/dist/smoothscroll.min.js" integrity="sha384-EYn4rWu1DHvYD0sSSSbMEtXQmMl58CFJd897806+RT1jJVYbhuZlZMN6yG9nCyFa" crossorigin="anonymous"></script>
  <script src="https://unpkg.com/smoothscroll-anchor-polyfill@1.3.2/dist/index.min.js" integrity="sha384-EY9NBEHCFbZANmPcTm7CgG8OhsFILy0VBLG85pF6OIpP42NVbZVNsFOc23PYTCkB" crossorigin="anonymous"></script>
  
  <script async src="/js/resume.js"></script>
  

  

  
</body>
</html>
